Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rifaximin
Drug ID BADD_D01938
Description Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
Indications and Usage Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
Marketing Status approved; investigational
ATC Code A07AA11; D06AX11
DrugBank ID DB01220
KEGG ID D02554
MeSH ID D000078262
PubChem ID 6436173
TTD Drug ID D04ITO
NDC Product Code 14501-0082; 17337-0043; 17337-0044; 73309-232; 17337-0032; 57297-029; 65649-303; 10695-011; 14501-0093; 65649-301; 12828-0089; 62207-017; 76278-1109; 50090-2445; 55154-6777; 59285-008; 70799-000; 73377-184; 14501-0021
UNII L36O5T016N
Synonyms Rifaximin | 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin | L 105 | L-105 | L105 | Redactiv | Xifaxan
Chemical Information
Molecular Formula C43H51N3O11
CAS Registry Number 80621-81-4
SMILES CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O )C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myalgia15.05.02.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Neck pain15.03.04.009--
Neoplasm malignant16.16.01.0010.001993%-
Nephrolithiasis20.04.01.0020.000322%
Nervous system disorder17.02.10.001---
Neutropenia01.02.03.004---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.0110.002443%
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pancreatic disorder07.18.02.0010.000707%-
Petechiae01.01.03.002; 23.06.01.003; 24.07.06.0040.000322%-
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003---
Pollakiuria20.02.02.0070.000707%
Polyuria20.02.03.002---
Portal hypertension09.01.06.006; 24.08.06.0010.000322%
Proctalgia07.03.02.001--
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rectal haemorrhage07.12.03.001; 24.07.02.0180.000804%
Renal disorder20.01.02.0020.000482%-
Renal failure20.01.03.0050.002733%-
Respiratory disorder22.02.07.0020.000643%-
Retching07.01.07.0020.000707%-
Rhinitis11.01.13.004; 22.07.03.006--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene